Description: Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)
Target Patient Population: Cancers with CCNE1 amplification, FBXW7 and or PPP2R1A deleterious mutations
Study Design: Drug is given orally. Gemcitabine is given IV Day 1, 8